Skip to Content

Optiray 350 (ioversol) Disease Interactions

There are 5 disease interactions with Optiray 350 (ioversol):


Iodinated radiopaque contrast agents (Includes Optiray 350) ↔ hyperthyroidism

Severe Potential Hazard, Moderate plausibility. Applies to: Hyperthyroidism

Reports of thyroid storm following the use of iodinated diagnostic agents in patients with hyperthyroidism or with an autonomously functioning thyroid nodule suggest that this additional risk be evaluated in such patients before the use of any contrast medium. Some agents such as ioversol are contraindicated in symptomatic hyperthyroidism.


Radiopaque contrast agents (Includes Optiray 350) ↔ pheochromocytoma

Severe Potential Hazard, Moderate plausibility. Applies to: Pheochromocytoma

Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution. If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium. The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.


Contrast agents (Includes Optiray 350) ↔ sickle cell disease

Moderate Potential Hazard, Moderate plausibility. Applies to: Sickle Cell Anemia

Some contrast agents have shown to promote the phenomenon of sickling (blood cell rupture) in individuals who are homozygous for sickle cell disease when administered intravenously or intra- arterially. Caution is advised.


Ioversol (Includes Optiray 350) ↔ acute renal failure

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction, Diabetes Mellitus, Multiple Myeloma, Congestive Heart Failure

Acute kidney injury, including renal failure, may occur after ioversol administration. Risk factors include preexisting renal impairment, dehydration, diabetes, congestive heart failure, advanced vascular disease, multiple myeloma, elderly age, and concomitant use of nephrotoxic or diuretic medications. The lowest dose of ioversol should be used in patients with renal impairment and other risk factors.


Ioversol (Includes Optiray 350) ↔ cardiovascular disease

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction, Congestive Heart Failure, Cardiovascular Disease, Liver Disease

Life-threatening or fatal cardiovascular reactions have occurred with the use of ioversol, including cardiac arrest, hypotensive collapse and shock. Most deaths have occurred following 10 minutes of the injection, and cardiovascular disease has been identified as the main underlying factor. Additionally, ioversol increases the circulatory osmotic load and may induce acute or delayed hemodynamic disturbances in patients with congestive heart failure, and severely impaired renal function with or without hepatic disease. Caution should be used when using ioversol in these patients and the lowest dose possible should be used.

Optiray 350 (ioversol) drug interactions

There are 240 drug interactions with Optiray 350 (ioversol)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.